Biotech · Private company
Eidos Therapeutics, a BridgeBio company
Track this companyFree. Adds Eidos Therapeutics, a BridgeBio company to your Dealase workspace and tells you when its record changes.
Clinical trials104 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- AcoramidisPhase 3 · AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- Acoramidis (AG10)Phase 3 · Amyloid Cardiomyopathy, Transthyretin-RelatedClinicalTrials.gov · fetched Nov 12, 2026
- AG10Phase 3 · Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- AcoramidisPhase 2 · Amyloid CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
- AG10Phase 2 · Familial ATTR-CM (ATTRm-CM, or FAC)ClinicalTrials.gov · fetched Nov 12, 2026
- AG10 oral tabletPhase 1 · Amyloid Cardiomyopathy, Transthyretin-RelatedClinicalTrials.gov · fetched Nov 12, 2026
- Acoramidis (AG10) oral tabletTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisPHASE4 · RECRUITING · started Jul 1, 2026ClinicalTrials.gov NCT07695701 · fetched Nov 12, 2026
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPHASE3 · RECRUITING · started May 12, 2025ClinicalTrials.gov NCT06563895 · fetched Nov 12, 2026
- Cardiac Amyloidosis Discovery TrialNA · COMPLETED · started May 28, 2024ClinicalTrials.gov NCT06469372 · fetched Nov 12, 2026
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 27, 2021ClinicalTrials.gov NCT04988386 · fetched Nov 12, 2026
- Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyPHASE3 · WITHDRAWN · started Oct 21, 2020ClinicalTrials.gov NCT04418024 · fetched Nov 12, 2026
- Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFNA · RECRUITING · started Oct 2, 2020ClinicalTrials.gov NCT05577819 · fetched Nov 12, 2026
- Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyPHASE3 · COMPLETED · started Mar 19, 2019ClinicalTrials.gov NCT03860935 · fetched Nov 12, 2026
- Open-Label Study of AG10 in Patients With CardiomyopathyPHASE2 · TERMINATED · started Aug 8, 2018ClinicalTrials.gov NCT03536767 · fetched Nov 12, 2026
- Study of AG10 in Amyloid CardiomyopathyPHASE2 · COMPLETED · started Apr 27, 2018ClinicalTrials.gov NCT03458130 · fetched Nov 12, 2026
- Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10PHASE1 · COMPLETED · started Sep 11, 2017ClinicalTrials.gov NCT03294707 · fetched Nov 12, 2026